What makes Owkin different?

Owkin is differentiated by a focus on building Biological Artificial Superintelligence (BASI) to improve our fundamental understanding of disease biology.

We believe this will be best achieved through analysis of multimodal patient data and its use in training cutting-edge AI, grounded in biology.

We have built an unrivalled network of leading researchers, academic centres and hospitals in order to access, understand and properly characterise our patient data.

Our AI scientist - K Pro - can analyze multimodal data, identify novel targets and biomarkers, report on the business environment for a given asset and much more.

We believe that all AI looking to understand disease biology must be grounded in reality - hence we test our AI models’ predictions with patients in the real world, through our INVOKE clinical trial and through our diagnostic partner Waiv.

By understanding complex biology through AI, we speed up pharmaceutical R&D, identify new treatments, and de-risk and accelerate clinical trials.